Bb5a31f81ClaimIn a clinical trial conducted through UC San Diego and UCLA, co-administration of Agarikon and Turkey Tail mycelium with COVID-19 mRNA vaccines statistically significantly reduced adverse reactionsAgreeDisagree
Bb5a31f81ClaimA ketogenic dietary intervention studied by Virta Health reversed type 2 diabetes in 60 percent of participating patientsAgreeDisagree
Bb5a31f81ClaimThe Women's Health Initiative clinical trial evaluating hormone replacement therapy revealed that prior observational studies were confounded by healthy user biasAgreeDisagree
Bb5a31f81ClaimMerck and Moderna's personalized melanoma vaccine contains messenger RNA encoding up to 34 selected tumor mutation proteinsAgreeDisagree
Bb5a31f81ClaimIn personalized cancer vaccine development, researchers sequence tumor DNA after surgical removal to identify patient-specific mutationsAgreeDisagree
Bb5a31f81ClaimPatients treated with Merck and Moderna's experimental melanoma vaccine were less likely to develop distant metastatic recurrence than untreated trial participantsAgreeDisagree
Bb5a31f81ClaimIn psilocybin mushroom clinical trials, a standard therapeutic dose is commonly established at 25 milligrams of psilocybin or approximately 2.5 grams of dried Psilocybe cubensisAgreeDisagree
Bb5a31f81ClaimClinical trials conducted by Compass Pathways showed an approximately 40 to 45 percent response rate for psilocybin therapy in treatment-resistant depressionAgreeDisagree
Bb5a31f81ClaimClinical trial data over two years showed patients receiving Merck and Moderna's experimental melanoma vaccine were 42 percent less likely to experience cancer recurrence compared to patients who did not receive the vaccineAgreeDisagree
Bb5a31f81ClaimA clinical trial for Merck and Moderna's experimental melanoma vaccine enrolled more than 1,100 patients with stage 2, stage 3, or stage 4 melanomaAgreeDisagree
Bb5a31f81ClaimMerck and Moderna developed an experimental melanoma vaccine and planned to seek approval from the United States Food and Drug AdministrationAgreeDisagree
Bb5a31f81ClaimPatients who received Merck and Moderna's experimental melanoma vaccine reported mild side effects consisting of sore arms and flu-like symptoms lasting one to two daysAgreeDisagree
Bb5a31f81ClaimIn symptomatic, unvaccinated COVID-19 patients, treatment with Agarikon and Turkey Tail mycelium was associated with symptom resolution 5.1 days faster than placeboAgreeDisagree
Bb5a31f81ClaimTumor mutations produce abnormal proteins on cancer cell surfaces that can trigger immune system recognition and attackAgreeDisagree
Bb5a31f81ClaimCancer cells are capable of evading detection and hiding from the human immune systemAgreeDisagree
Bb5a31f81ClaimImmune checkpoint inhibitors are therapeutic drugs designed to release natural biological brakes on the immune system that cancer cells exploitAgreeDisagree
Bb5a31f81ClaimPersonalized mRNA cancer vaccines provide genetic instructions directing the patient's cells to produce specific tumor proteins and stimulate an immune responseAgreeDisagree
Bb5a31f81ClaimMerck and Moderna's experimental melanoma vaccine was administered to clinical trial patients in combination with an immune checkpoint inhibitor drugAgreeDisagree
Bb5a31f81ClaimClinical trials demonstrate that patients taking SGLT2 inhibitors lose an average of five to eight poundsAgreeDisagree
Bb5a31f81ClaimHenagliflozin treatment in a 26-week trial increased levels of Granzyme B in immune killer T cellsAgreeDisagree